financetom
Business
financetom
/
Business
/
Market Chatter: Groupe Dynamite Aims for $1.7 Billion Valuation in Canadian IPO
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Market Chatter: Groupe Dynamite Aims for $1.7 Billion Valuation in Canadian IPO
Nov 11, 2024 1:14 PM

03:59 PM EST, 11/11/2024 (MT Newswires) -- Canadian women's clothing retailer Groupe Dynamite Inc. launched its initial public offering with a dual-class share structure and a valuation of C$2.3 billion ($1.7 billion), a deal that would cement its top executive as a billionaire, Bloomberg is reporting Monday.

The company behind the Garage and Dynamite chains said in public filings that Andrew Lutfy, its owner and chief executive officer, expects to offer subordinate voting shares in the range of C$19 to C$23 per share, which would raise about C$300 million based on the midpoint.

Lutfy would retain about 87% of the company and 98.5% of the voting rights, assuming the underwriters don't exercise an option to sell more shares. If the IPO goes at C$21, the company's market capitalization would be C$2.3 billion, making Lutfy's stake worth C$2 billion.

Bloomberg noted the company will list on the Toronto Stock Exchange and trade under the symbol GRGD. The offering is being led by Goldman Sachs Canada Inc., BMO Nesbitt Burns Inc., RBC Dominion Securities Inc. and TD Securities Inc., with other institutions including Scotia Capital Inc. and Desjardins Securities Inc. part of the underwriting.

Groupe Dynamite, with about 6,000 employees, operates nearly 300 stores in US and Canada selling fashion-forward clothing that's marketed using bold, youthful imagery.

(Market Chatter news is derived from conversations with market professionals globally, and/or from other media sources. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Universal Electronics CEO Paul Arling to Retire
Universal Electronics CEO Paul Arling to Retire
Mar 21, 2025
07:15 AM EDT, 03/21/2025 (MT Newswires) -- Universal Electronics ( UEIC ) said Friday that Chief Executive Officer Paul Arling will retire on April 30. The company said Arling will continue to serve as a consultant until June 30 and remain on the board until his term ends at the 2025 annual shareholder meeting. Universal Electronics ( UEIC ) said...
G2S2 Capital Sells 50,000 Shares in Knight Therapeutics
G2S2 Capital Sells 50,000 Shares in Knight Therapeutics
Mar 21, 2025
07:10 AM EDT, 03/21/2025 (MT Newswires) -- Knight Therapeutics ( KHTRF ) overnight Thursday said G2S2 Capital sold 50,000 Knight shares through the Toronto Stock Exchange at $6.40 each. The disposal lowers G252's stake in Knight Therapeutics ( KHTRF ) to just above 10%. ...
Update: Market Chatter: AT&T, Others Approached by UK's BT About International Unit Tie-Up
Update: Market Chatter: AT&T, Others Approached by UK's BT About International Unit Tie-Up
Mar 21, 2025
06:50 AM EDT, 03/21/2025 (MT Newswires) -- (Updates with BT's response in the third paragraph.) AT&T ( T ) is among the major telecommunications companies that have been approached by the UK's BT Group about possible partnerships involving its international business, Bloomberg News reported, citing people familiar with the matter. The British firm is looking for potential partners to weigh...
Telix Pharmaceuticals Says FDA Approves New Drug Application for Prostate Cancer Imaging Agent Gozellix
Telix Pharmaceuticals Says FDA Approves New Drug Application for Prostate Cancer Imaging Agent Gozellix
Mar 21, 2025
07:13 AM EDT, 03/21/2025 (MT Newswires) -- Telix Pharmaceuticals ( TLX ) said Friday that the US Food and Drug Administration has approved its new drug application for Gozellix, a PSMA-PET imaging agent for prostate cancer. Gozellix is indicated for PET scanning of PSMA positive lesions in men having prostate cancer which may have metastasized and are eligible for initial...
Copyright 2023-2026 - www.financetom.com All Rights Reserved